Antibacterial drug discovery in the resistance era

By Eric D. Brown, Gerard D. Wright. Nature, 2016

1,950 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Molecular Medicine, Pharmacology

View Paper: https://www.semanticscholar.org/paper/766150b00dc038b24cc3ff9715c60f42b98b7254

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

In Molecular Medicine

In Pharmacology

Citations in the corpus

CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database (2016, background): “As a consequence, AMR has become a global health crisis, exacerbated by a faltering drug discovery pipeline (2).”
Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection (2017, background): “discover infectious disease therapeutics with novel mechanisms of action (7, 8).”
A new antibiotic selectively kills Gram-negative pathogens (2019, neutral): “Since then, discovery has been largely limited to narrow-spectrum compounds 2,6 .”
A Deep Learning Approach to Antibiotic Discovery. (2020, positive): “Moreover, the decreasing development of new antibiotics in the private sector that has resulted from a lack of economic incentives is exacerbating this already dire problem (Brown and Wright, 2016; PEW Trusts, 2019).”
A Comprehensive Review on Medicinal Plants as Antimicrobial Therapeutics: Potential Avenues of Biocompatible Drug Discovery (2019, background): “claim could return to the level of the pre-antibiotic era [3].”
CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database (2019, background): “However, antibiotic misuse and poor stewardship have turned antimicrobial resistance (AMR) into a global health crisis, exacerbated by a withered antibiotic discovery pipeline (5).”
A deep learning approach to antibiotic discovery (2020, background): “Concurrently, the steadily declining productivity in clinically implementing new antibiotics due to the high risk of early discovery and low return on investment is exacerbating this problem (E. D. Brown and Wright, 2016).”
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics (2024, neutral): “During the golden age of antibiotic discovery, the relative proliferation of new classes of antibiotics in a relatively short span of time seemed to promise an unending number of new antimicrobial compounds 2 .”